Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Proteon ups Phase III PATENCY-2 enrollment

May 12, 2017 8:36 PM UTC

Proteon Therapeutics Inc. (NASDAQ:PRTO) will for the second time increase enrollment in the ongoing Phase III PATENCY-2 trial of vonapanitase to treat chronic kidney disease (CKD) to correct a calculation error in the trial’s statistical plan. The trial will now enroll 600 CKD patients undergoing surgery for arteriovenous fistula (AVF) creation, up from 500 previously. Proteon said the error had overstated the trial’s power to evaluate the co-primary endpoint of secondary patency, defined as the time from creation until fistula abandonment. The trial’s other co-primary endpoint will assess fistula use for hemodialysis.

The double-blind, placebo-controlled, North American trial is evaluating vonapanitase given immediately after radiocephalic AVF. Vonapanitase is recombinant human elastase...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Proteon Therapeutics Inc.

BCIQ Target Profiles

Elastin (ELN)